3 recruiting, 1 active not recruiting, 1 completed. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Fuchs: new trials by email Literature Review of Fuchs trials Research Report on Fuchs
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction 150K cells, 500K cells, Placebo - Corneal Edema, Fuchs | Phase 2 | Recruiting | Emmecell | 121 | 2026-10-01 | 2026-10-09 |
| DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy DT-168 - Fuchs Endothelial Corneal Dystrophy, Fuchs | Phase 2 | Recruiting | Design Therapeutics, Inc. | 70 | 2025-07-30 | 2026-09-28 |
| Descemet Endothelial Thickness Comparison Trial II Ripasudil, Placebo - Fuchs, Fuchs Dystrophy | Phase 3 | Recruiting | Stanford University | 60 | 2023-01-23 | 2026-08-17 |
| Descemet Endothelial Thickness Comparison Trial I Topical Ripasudil, Topical Placebo - Fuchs | Phase 3 | Active not recruiting | Stanford University | 160 | 2022-07-15 | 2026-08-17 |
| TTHX1114(NM141) in Combination With DWEK/DSO TTHX1114(NM141) - Fuchs' Endothelial Dystrophy, Fuchs Dystrophy | Phase 2 | Completed | Trefoil Therapeutics, Inc. | 49 | 2021-02-01 | 2023-11-07 |
Fuchs' Endothelial Dystrophy (4) · Corneal Edema (1) · Corneal Endothelial Cell Loss (1) · Corneal Endothelial Dystrophy 1 (1) · Corneal endothelial dystrophy type 2 (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Corneal Diseases (4) · Corneal Dystrophies, Hereditary (4) · Eye Diseases (4) · Eye Diseases, Hereditary (4) · Genetic Diseases, Inborn (4) · Eye Manifestations (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Postoperative Complications (1) · Signs and Symptoms (1)
K-115 (2)
Stanford University (2) · Design Therapeutics, Inc. (1) · Emmecell (1) · Trefoil Therapeutics, Inc. (1)
United States (5)
Jennifer Rose-Nussbaumer, MD (2) · Noelia Kunzevitzky, PhD (1) · Thomas Tremblay (1)